Organigram Holdings Inc. (TSE:OGI - Get Free Report) hit a new 52-week low during trading on Friday . The stock traded as low as C$1.49 and last traded at C$1.51, with a volume of 122296 shares. The stock had previously closed at C$1.54.
Several equities analysts have issued reports on OGI shares. Canaccord Genuity Group decreased their price objective on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating on the stock in a report on Monday, December 9th. ATB Capital decreased their price target on shares of Organigram from C$5.25 to C$3.50 in a research note on Tuesday, December 17th.
Get Our Latest Research Report on Organigram
The company has a market cap of C$189.02 million, a PE ratio of -3.23, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The business has a fifty day simple moving average of C$2.09 and a two-hundred day simple moving average of C$2.26. The company has a current ratio of 3.36, a quick ratio of 2.62 and a debt-to-equity ratio of 3.07.
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.